Company: CERO
Filing Date: 2025-07-14
Form Type: 424B3
Source: 0001213900-25-063764
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-14
Form: 424B3
Chunk 2
---
ement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: |

| Title of each class                                                                  |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                                            |     | CERO              |     | Nasdaq Capital Market                     |
| Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock |     | CEROW             |     | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

As previously
disclosed, on June 11, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter (the
“Bid Price Requirement Letter”) from the Listing Qualifications Department (the “Staff”) at The Nasdaq Stock Market
(“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between April 25, 2025 through June 9, 2025,
the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”) was below the
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2), which
is required for continued listing of the Common Stock on Nasdaq (the “Bid Price Requirement”).

The
Company timely appealed the Staff’s delisting determination by requesting a hearing before a Hearings Panel (the “Panel”).
Such request by the Company for a Panel hearing stayed the suspension of the Company’s securities.

On July
7, 2025, Nasdaq informed the Company that the Staff had determined that the Company has regained compliance with the Bid Price Requirement
and is therefore in compliance with the continued listing requirements.